ストックスクリーナーアプリを入手
0.8302
2.33%
-0.0198
アフターアワーズ：
.83
-0.0002
-0.02%
前日終値:
$0.85
開ける：
$0.8501
24時間の取引高:
152.10K
Relative Volume:
0.20
時価総額：
$68.65M
収益：
$38.70M
当期純損益:
$-117.88M
株価収益率:
-0.4884
EPS:
-1.7
ネットキャッシュフロー:
$-92.84M
1週間 パフォーマンス:
+8.37%
1か月 パフォーマンス:
-3.42%
6か月 パフォーマンス:
-41.94%
1年 パフォーマンス:
-64.67%
1日の値動き範囲:
$0.82
$0.862
1週間の範囲:
$0.82
$0.95
52週間の値動き範囲:
$0.7407
$2.43
Adicet Bio Inc Stock (ACET) Company Profile
ACET を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ACET
Adicet Bio Inc
|
0.8302 | 68.65M | 38.70M | -117.88M | -92.84M | -1.70 |
|
VRTX
Vertex Pharmaceuticals Inc
|
492.69 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
637.36 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
589.15 | 35.93B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
268.46 | 34.75B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
267.39 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Adicet Bio Inc Stock (ACET) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-09-30 | 再開されました | Guggenheim | Buy |
| 2024-09-11 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2023-06-27 | ダウングレード | Guggenheim | Buy → Neutral |
| 2023-06-27 | ダウングレード | JMP Securities | Mkt Outperform → Mkt Perform |
| 2023-06-01 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2022-09-21 | 開始されました | JP Morgan | Overweight |
| 2022-03-31 | 開始されました | SMBC Nikko | Outperform |
| 2022-03-08 | 開始されました | Truist | Buy |
| 2022-03-04 | 開始されました | Jefferies | Buy |
| 2021-05-18 | 開始されました | BTIG Research | Buy |
| 2021-04-23 | 開始されました | H.C. Wainwright | Buy |
| 2021-04-14 | 開始されました | Canaccord Genuity | Buy |
| 2021-04-08 | 開始されました | Guggenheim | Buy |
| 2020-11-04 | 開始されました | B. Riley Securities | Buy |
| 2020-10-27 | 開始されました | JMP Securities | Mkt Outperform |
| 2020-10-16 | 開始されました | Wedbush | Outperform |
すべてを表示
Adicet Bio Inc (ACET) 最新ニュース
The Royal Office of H.H. Sheikh Ahmed Bin Faisal Al-Qassimi and ACET ($ACT) Drive Blockchain Payment Innovation in UAE’s $3.9 Billion USD Initiative - GlobeNewswire Inc.
Adicet Bio (NASDAQ:ACET) Earns “Buy” Rating from Guggenheim - Armenian Reporter
Adicet Bio (ACET): Among the Penny Stocks With Huge Upside Potential According to Analysts - Insider Monkey
Guggenheim Reiterates Buy Rating for Adicet Bio (NASDAQ:ACET) - Defense World
10 Penny Stocks With Huge Upside Potential According To Analysts - Insider Monkey
Short Interest in Adicet Bio, Inc. (NASDAQ:ACET) Drops By 16.9% - Defense World
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Adicet Bio’s SWOT analysis: gamma-delta T cell stock faces pivotal year - Investing.com Canada
Adicet Bio’s SWOT analysis: gamma-delta T cell stock faces pivotal year By Investing.com - Investing.com South Africa
Adicet Bio (ACET) Expected to Announce Earnings on Tuesday - Defense World
Promising Pipeline and Strong Financials Drive Buy Rating for Adicet Bio - TipRanks
Adicet Bio (NASDAQ:ACET) Earns “Neutral” Rating from HC Wainwright - Defense World
Adicet Bio Advances Clinical Trials and Financial Stability - TipRanks
H.C. Wainwright maintains Neutral on Adicet Bio stock By Investing.com - Investing.com South Africa
H.C. Wainwright maintains Neutral on Adicet Bio stock - Investing.com India
Cautious Hold Rating on Adicet Bio Amid Early-Stage Clinical Developments and Uncertain Outcomes - TipRanks
Adicet Bio: Hold Rating Amid Fair Valuation and Awaited Clinical Data - TipRanks
Adicet Bio Inc Files For Mixed Shelf Of Up To $250 Million -March 06, 2025 at 04:59 pm EST - Marketscreener.com
Adicet Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Company Progress - Lelezard
Adicet Bio, Inc Q4 Loss Decreases - Nasdaq
Adicet Bio reports Q4 EPS (32c), consensus (35c) - TipRanks
Can Adicet Bio's $176M War Chest and Fast Track Status Transform Autoimmune Treatment? - StockTitan
Adicet Bio, Inc. (NASDAQ:ACET) Receives $7.50 Average Target Price from Analysts - Defense World
Adicet Bio, Inc. (NASDAQ:ACET) Short Interest Update - Defense World
Adicet Announces Poster Presentations Highlighting ADI-270 Data at the Society for Immunotherapy of Cancer (SITC) 2025 Spring Scientific Meeting - BioSpace
Adicet Bio's (ACET) "Neutral" Rating Reaffirmed at HC Wainwright - MarketBeat
Adicet Bio shares rise on FDA Fast Track Designation for ADI-001 - Investing.com
FDA fast tracks Adicet Bio's autoimmune therapy By Investing.com - Investing.com South Africa
FDA fast tracks Adicet Bio’s autoimmune therapy - Investing.com
Adicet Bio Receives FDA Fast Track Designation for ADI-001 for the Treatment of Systemic Sclerosis (SSc) - Lelezard
FDA fast tracks Adicet Bio’s autoimmune therapy By Investing.com - Investing.com UK
Adicet's Systemic Sclerosis Therapy Earns Critical FDA Fast Track StatusWhat This Means for Patients - StockTitan
Adicet Bio (NASDAQ:ACET) versus Corvus Pharmaceuticals (NASDAQ:CRVS) Head to Head Analysis - Defense World
Adicet Bio's SWOT analysis: gamma-delta T cell stock faces pivotal year By Investing.com - Investing.com South Africa
Adicet Bio's SWOT analysis: gamma-delta T cell stock faces pivotal year - Investing.com
Healthy Upside Potential: Adicet Bio Inc (ACET) - SETE News
Adicet Bio Inc [ACET] Insider Activity: An Update for Investors - Knox Daily
Investor Alert: What’s Really Going On At Adicet Bio Inc (NASDAQ: ACET) - Stocks Register
Adicet Bio (NASDAQ:ACET) Earns Market Perform Rating from JMP Securities - MarketBeat
Brokerages Set Adicet Bio, Inc. (NASDAQ:ACET) PT at $7.50 - MarketBeat
Adicet Bio reports progress in clinical trial enrollments - MSN
HC Wainwright Reaffirms Neutral Rating for Adicet Bio (NASDAQ:ACET) - MarketBeat
Adicet Bio (NASDAQ:ACET) Earns “Market Perform” Rating from JMP Securities - Defense World
Top investors say Adicet Bio Inc (ACET) ticks everything they need - SETE News
Major Win – FDA Grants Fast Track Designation to Adicet Bio’s ADI-001 for Lupus Disease - geneonline
Adicet Bio Inc [NASDAQ: ACET] Sees Increase in Stock Value - Knox Daily
Adicet Bio Inc (ACET) 財務データ
収益
当期純利益
現金流量
EPS
0.39%
0.34%
大文字化:
|
ボリューム (24 時間):